The pooled evidence from observational and retrospective cohort studies suggests that SGLT2 inhibitors confer significant reductions in mortality, HF hospitalizations, and composite cardiovascular events, even in populations exposed to cardiotoxic cancer therapies such as anthracyclines or immune checkpoint inhibitors. This evidence concerns the gene SLC5A2 and hydrops fetalis.